AdvisorShares Investments LLC lifted its stake in shares of GH Research PLC (NASDAQ:GHRS – Get Rating) by 36.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 19,374 shares of the company’s stock after acquiring an additional 5,132 shares during the quarter. AdvisorShares Investments LLC’s holdings in GH Research were worth $354,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in GHRS. Virtus ETF Advisers LLC purchased a new stake in shares of GH Research during the 4th quarter worth approximately $165,000. Point72 Asset Management L.P. purchased a new stake in shares of GH Research during the 4th quarter worth approximately $7,256,000. Deep Track Capital LP purchased a new stake in shares of GH Research during the 4th quarter worth approximately $11,651,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of GH Research during the 4th quarter worth approximately $3,168,000. 78.06% of the stock is currently owned by institutional investors.
GH Research Stock Up 29.8 %
Shares of GH Research stock opened at $15.80 on Friday. The stock’s fifty day moving average is $11.01 and its two-hundred day moving average is $14.29. The company has a market capitalization of $798.22 million, a PE ratio of -54.48 and a beta of 1.37. GH Research PLC has a 52 week low of $8.72 and a 52 week high of $30.43.
Wall Street Analysts Forecast Growth
Several analysts have recently issued reports on the company. Canaccord Genuity Group decreased their price objective on GH Research from $45.00 to $41.00 and set a “buy” rating on the stock in a report on Wednesday, April 13th. Roth Capital assumed coverage on GH Research in a report on Wednesday, June 15th. They set a “buy” rating and a $66.00 price target on the stock.
GH Research Company Profile
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
- Get a free copy of the StockNews.com research report on GH Research (GHRS)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.